4-氯-2,5-二甲氧基-苯甲醛 | 90064-48-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氯-2,5-二甲氧基-苯甲醛
• 英文名称: 4-chloro-2,5-dimethoxybenzaldehyde
• CAS: 90064-48-5
• 化学式: C₉H₉ClO₃
• 分子量: 200.622
• InChiKey: VWSPFJJLIGAHLK-UHFFFAOYSA-N

物化性质

• 熔点：
  112-114 °C
• 沸点：
  322.4±37.0 °C(Predicted)
• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2913000090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  存储条件为2-8°C，并需保存在惰性气体环境中。

SDS

Name:	4-Chloro-2 5-Dimethoxybenzaldehyde 98% Material Safety Data Sheet
Synonym:
CAS:	90064-48-5

Section 1 - Chemical Product MSDS Name:4-Chloro-2 5-Dimethoxybenzaldehyde 98% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
90064-48-5	4-Chloro-2,5-Dimethoxybenzaldehyde	98	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed.
Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 90064-48-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Not available.
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula:
Molecular Weight:

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stability unknown.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 90064-48-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Chloro-2,5-Dimethoxybenzaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 90064-48-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 90064-48-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 90064-48-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氯-2,5-二甲氧基-苯甲醛 在 EtOH sodium hydroxide 、 ammonium cerium(IV) nitrate 、 sodium acetate 、 sodium hydride 作用下， 以 乙醇 、 水 、 甲苯 、 乙腈 为溶剂， 反应 34.0h， 生成 4-hydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
  参考文献：
  名称：

  Preparation of functionalized juglone acetates and juglones via 1,4-dimethoxynaphthalene derivatives: synthesis of anthraquinones related to rhein and aloe-emodin

  摘要：

  DOI：

  10.1021/jo00079a042
• 作为产物：
  描述：

  甲基氢醌 在 sodium disulfite 、 N-溴代丁二酰亚胺(NBS) 、 磺酰氯 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 生成 4-氯-2,5-二甲氧基-苯甲醛
  参考文献：
  名称：

  An efficient route to 3-chlorojuglones

  摘要：

  DOI：

  10.1016/s0040-4039(00)72715-8

文献信息

• [EN] MLKL INHIBITORS<br/>[FR] INHIBITEURS MLKL
  申请人：NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING

  公开号：WO2018157800A1

  公开（公告）日：2018-09-07

  Purine derivatives that inhibit cellular necroptosis and/or human MLKL, pharmaceutical compositions thereof, and methods of treating an MLKL-mediated disorder with an effective amount of the compound or composition. Said MLKL-mediated disorder is pathology associated necroptosis, including ischemia-reperfusion damage, neurodegeneration, and inflammatory diseases such as acute pancreatitis, multiple sclerosis, inflammatory bowel disease, and allergic colitis.

  嘌呤衍生物，用于抑制细胞坏死性凋亡和/或人类MLKL；包含该衍生物的药物组合物；以及使用有效量的该化合物或组合物治疗MLKL介导的疾病的方法。所述MLKL介导的疾病是与坏死性凋亡相关的病理学，包括缺血再灌注损伤、神经退行性疾病、以及诸如急性胰腺炎、多发性硬化症、炎症性肠病和过敏性结肠炎等炎症性疾病。
• Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A
  作者：Yi Zheng、Xia Li、Piyusha P. Pagare、Yunyun Yuan、Xiang-Yang Wang、Yan Zhang

  DOI：10.1016/j.bmcl.2016.11.029

  日期：2017.1

  Scavenger receptor A (SRA) has been known as an immunosuppressive factor and therefore therapeutic inhibition of SRA may be potentially exploited for cancer immunotherapy. Our previously work suggested that rhein may act as an inhibitor of SRA in reversing immunosuppression of SRA during T cells activation. Herein, three deconstruction analogs of rhein, compound 1, 2, and 3, were further studied as

  清道夫受体A（SRA）是一种免疫抑制因子，因此对SRA的治疗性抑制可能会被用于癌症免疫治疗。我们以前的工作表明，大黄酸可能在T细胞活化过程中逆转SRA的免疫抑制中起SRA抑制剂的作用。这里，大黄酸，化合物三个解构类似物1，2，和3，进一步研究了如SRA的抑制剂。这三种化合物，特别是化合物1，也称为天然产物丹磺隆，可增强T细胞活化，这是由白介素2（Il2）基因，IL-2蛋白的产生以及T细胞的增殖。此外，通过分子建模研究了这些化合物与SRA之间的相互作用。化合物1表现出与比较化合物SRA蛋白的富含半胱氨酸结构域的有利结合模式2和3。总而言之，这些结果将为作为SRA抑制剂的下一代大黄酸衍生物的未来设计和开发提供见识。
• Synthesis of Pluraflavin A “Aglycone”
  作者：Benjamin J. D. Wright、John Hartung、Feng Peng、Ryan Van de Water、Haibo Liu、Quen-Hui Tan、Ting-Chao Chou、Samuel J. Danishefsky

  DOI：10.1021/ja805936v

  日期：2008.12.10

  The "aglycone" of pluraflavin A (2) has been synthesized. The key features of this synthesis include a 1,3-dipolar cycloaddition between a nitrile oxide (cf. 14) and an olefin (22) to yield an isoxazoline followed by subsequent conversion into the gamma-pyrone of pluraflavin A. The epoxide moiety linked to the pyrone is installed prior to Diels-Alder installation of the D ring, which allows access

  已合成多黄素 A (2) 的“苷元”。该合成的关键特征包括腈氧化物（参见 14）和烯烃（22）之间的 1,3-偶极环加成反应生成异恶唑啉，随后转化为多黄素 A 的 γ-吡喃酮。连接的环氧化物部分在 Diels-Alder 安装 D 环之前安装到吡喃酮，这允许在到达最终化合物的途中获得许多潜在的活性细胞毒性中间体。两种此类化合物的初步体外结果也包括在外消旋标题化合物中，显示出纳摩尔范围的细胞毒性。
• Ethyl(or methyl) 4-acetoxy(or propionyloxy)-5,6,7 or 8-di(or
  申请人：Temple University of the Commonwealth System of Higher Education

  公开号：US04975463A1

  公开（公告）日：1990-12-04

  Novel antiviral ring-substituted ethyl or methyl 4-acetoxy (or propionyloxy)-2-naphthoates are provided.

  提供了一种新型抗病毒的环取代乙基或甲基4-乙酰氧基（或丙酰氧基）-2-萘酸酯。
• Geographic Variability and Anti-Staphylococcal Activity of the Chrysophaentins and Their Synthetic Fragments
  作者：Jessica L. Keffer、Jared T. Hammill、John R. Lloyd、Alberto Plaza、Peter Wipf、Carole A. Bewley

  DOI：10.3390/md10051103

  日期：——

  Drug-resistant Staphylococcus aureus is a continuing public health concern, both in the hospital and community settings. Antibacterial compounds that possess novel structural scaffolds and are effective against multiple S. aureus strains, including current drug-resistant ones, are needed. Previously, we have described the chrysophaentins, a family of bisdiarylbutene macrocycles from the chrysophyte alga Chrysophaeum taylori that inhibit the growth of S. aureus and methicillin-resistant S. aureus (MRSA). In this study we have analyzed the geographic variability of chrysophaentin production in C. taylori located at different sites on the island of St. John, U.S. Virgin Islands, and identified two new linear chrysophaentin analogs, E2 and E3. In addition, we have expanded the structure activity relationship through synthesis of fragments comprising conserved portions of the chrysophaentins, and determined the antimicrobial activity of natural chrysophaentins and their synthetic analogs against five diverse S. aureus strains. We find that the chrysophaentins show similar activity against all S. aureus strains, regardless of their drug sensitivity profiles. The synthetic chrysophaentin fragments indeed mimic the natural compounds in their spectrum of antibacterial activity, and therefore represent logical starting points for future medicinal chemistry studies of the natural products and their analogs.

  耐药性金黄色葡萄球菌仍然是一个持续的公共卫生问题，无论是在医院还是社区环境中。需要具有新型结构骨架的抗菌化合物，这些化合物能有效对抗包括当前耐药菌株在内的多种金黄色葡萄球菌株。我们之前描述了黄藻类藻类Chrysophaeum taylori中一种名为chrysophaentins的双芳基丁烯大环家族，这些化合物可以抑制金黄色葡萄球菌及耐甲氧西林金黄色葡萄球菌（MRSA）的生长。在本研究中，我们分析了位于美国维尔京群岛圣约翰岛不同地点的C. taylori中chrysophaentin的地理变异性，并鉴定了两种新的线性chrysophaentin类似物，E2和E3。此外，我们通过合成包含chrysophaentins保守部分的片段，扩展了结构-活性关系，并确定了天然chrysophaentins及其合成类似物对五种不同金黄色葡萄球菌株的抗菌活性。我们发现，chrysophaentins对所有金黄色葡萄球菌株的活性相似，无论其耐药性特征如何。合成的chrysophaentin片段的确在抗菌活性谱上模仿了天然化合物，因此为未来对天然产品及其类似物的药物化学研究提供了合理的起点。